MedPath

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

Phase 1
Completed
Conditions
Psoriasis
Interventions
Registration Number
NCT00563524
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Brief Summary

The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
76
Inclusion Criteria
  • Men and Women of nonchildbearing potential 18 years or older.
  • Physician Area and Severity Index (PASI) greater than 11.
  • Physician Global Assessment (PGA) greater than 3.
Exclusion Criteria
  • Use of any investigational small -molecule drug within 30 days before the first dose of test article administration, and use of any investigational biologic agents within 5 half lives before study day 1, or 90 days for investigational biologics that may have a long clinical duration of effect.
  • Live vaccines within 3 months before test article administration or during the study.
  • Use of any biologic therapy within approximately 5 half-lives before test article administration. Approximate half-lives of biologic therapies approved for psoriasis are as follows: Enbrel, 5 days; Humira, 14 days; Remicade, 9 days; Amevive, 12 days; Raptiva, 6 days. It is recommended that Amevive be discontinued for at least 90 days because of its long clinical duration of action.
  • Psoralen plus ultraviolet A radiation (PUVA) therapy within 4 weeks before study day 1.
  • Ultraviolet B (UVB) therapy within 2 weeks before study day 1.
  • Receipt of systemic psoriasis therapy (eg, oral retinoids, methotrexate, hydroxyurea, cyclosporine, or azathioprine) or systemic corticosteroids within 4 weeks before study day 1.
  • Topical steroids, topical vitamin A or D analog preparations, or anthralin within 2 weeks before study day 1. (Exception: topical therapies, including steroids at no higher than mild strength [class 6 or 7 topical corticosteroids], are permitted on the scalp, axillae, face, and groin, but the dose of the medication must be kept stable throughout the trial.)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1ILV-094-
Primary Outcome Measures
NameTimeMethod
Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)Day 1 up to Day 126

An AE was any untoward medical occurrence attributed to a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the end of study (Day 126), that were absent before treatment or that worsened relative to pre-treatment state. AEs include both SAEs and all non-SAEs.

Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) ParametersDay 1 up to Day 126

Clinically significant ECG findings included: heart rate (HR): less than or equal to (\<=) 45 beats per minute (bpm) or greater than or equal to (\>=)120 bpm or decrease/increase of \>=15 bpm from baseline value, PR interval: \>=220 millisecond (msec) and change of \>=20 msec from baseline value and; QRS interval \>=120 msec; corrected QT (QTc) interval for men greater than (\>) 450 msec, QTc interval for women \>470 msec.

Number of Participants With Laboratory Test Values of Potential Clinical ImportanceDay 1 up to Day 126

Criteria:Hematocrit:5% decrease from baseline,Hemoglobin:decrease of \>=20 gram per liter(g/L) from baseline,WBC: \<3.0\*10\^9/L;neutrophils: \<1.5\*10\^9/L,platelet count:\<100\*10\^9/L,eosinophils: \>0.5\*10\^9/L;prothrombin time,partial thromboplastin time: \>1.5\*Upper limit of normal(ULN);sodium,potassium: \>5millimoles per liter(mmol/L)aboveULN/below lower limit of normal(LLN),creatinine: \>1.36\*ULN,urea: \>1.5\*ULN,glucose(fasting): \>0.83mmol/L above ULN/below ULN,glucose (non-fasting): \>5.0 mmol/L above ULN/\>0.56 mmol/L below LLN,calcium:change of \>=0.25 mmol/L from baseline,magnesium:change at \>=0.21mmol/L from baseline value,phosphorus:\>0.162 mmol/L above ULN/below LLN,total protein:change of \>=20 g/L from baseline,albumin:change of \>=10 g/L from baseline,uric acid:change of \>0.119mmol/L from baseline,creatine kinase: \>3\*ULN,cholesterol: \>7.77mmol/L,triglycerides:\>3.39mmol/L;ALT,AST,total bilirubin: \>2\*ULN,alkaline phosphatase: \>1.5\*ULN,Gamma-glutamyl transferase,lactate dehydrogenase: \>3\*ULN.

Number of Participants With Vital Sign Values of Potential Clinical Importance (PCI)Day 1 up to Day 126

Criteria for identifying vital sign values of PCI: heart rate: increase of \>15 bpm from baseline value and \>=120 bpm and decrease of \>15 bpm from baseline value and \<=45 bpm; Sitting and Supine systolic blood pressure (SBP): increase of \>=20 millimeters of mercury (mm Hg) from baseline value and \>=160 mm Hg and decrease of \>=20 mm Hg from baseline value and \<=90 mm Hg; Sitting and Supine diastolic blood pressure (DBP): increase of \>=15 mm Hg from baseline value and \>=100 mm Hg and decrease of \>=15 mm Hg from baseline value and \<=50 mm Hg; Respiratory rate: \<10 or \>25 breaths/minute; Weight: \>=7 percent increase or decrease from baseline value; Oral temperature: \<35 degree Celsius (C) or \>38.3 degree C.

Secondary Outcome Measures
NameTimeMethod
Terminal-phase Disposition Rate Constant of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14

The terminal-phase disposition rate constant measured by a log-linear regression of the terminal mono exponential portion of the observed plasma concentrations, expressed in 1/day.

Terminal Half-Life (t1/2) of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14

Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half.

Area Under the Curve From Time Zero to 312 Hours [AUC (0-312)] Postdose of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312 hours post-dose

AUC (0-312) = Area under the plasma concentration time-curve from time zero (pre-dose) to 312 hours (0-312) postdose of ILV-094.

Average Observed Plasma Concentration (Cavg) of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14

Cavg was the average plasma concentration of drug during the dosing interval.

Serum C-Reactive Protein (CRP) LevelsDay 1, 14, 28, 42, 56

CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation.

Accumulation Ratio (Rac) of ILV-094Day 1: pre-dose, 1, 2, 3, 4, 8, 24, 48, 96, 144, 192, 240, 312 hours post-dose; Day 42: pre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312 hours post-dose

Rac was estimated as: X\*AUClast of Day 1 divided by AUC312 of Day 42, where X is the ratio of the maintenance dose to the loading dose of ILV-094, AUClast is defined as area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration and AUC-312 is the AUC from time 0 to 312 hours on Day 42.

Time to Reach Maximum Observed Plasma Concentration (Tmax) of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14
Terminal-phase Disposition Rate Constant of ILV-094: Single DosePre-dose, 1, 2, 3, 4, 8, 24, 48, 96, 144, 192, 240, 312 hours post-dose on Day 1

The terminal-phase disposition rate constant measured by a log-linear regression of the terminal mono exponential portion of the observed plasma concentrations, expressed in 1/day.

Terminal Half-Life (t1/2) of ILV-094: Single DosePre-dose, 1, 2, 3, 4, 8, 24, 48, 96, 144, 192, 240, 312 hours post-dose on Day 1

Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half.

Serum Interleukin-6 (IL-6) LevelsDay 1, 14, 28, 42, 56
Serum Amyloid-A LevelsDay 1, 14, 28, 42, 56
Maximum Observed Plasma Concentration (Cmax) of ILV-094: Single DosePre-dose, 1, 2, 3, 4, 8, 24, 48, 96, 144, 192, 240, 312 hours post-dose on Day 1
Maximum Observed Plasma Concentration (Cmax) of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14
Time to Reach Maximum Observed Plasma Concentration (Tmax) of ILV-094: Single DosePre-dose, 1, 2, 3, 4, 8, 24, 48, 96, 144, 192, 240, 312 hours post-dose on Day 1
Area Under the Curve From Time Zero to The Time of Last Quantifiable Concentration (AUClast) of ILV-094: Single DosePre-dose, 1, 2, 3, 4, 8, 24, 48, 96, 144, 192, 240, 312 hours post-dose on Day 1

AUClast is defined as area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration.

Apparent Clearance of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after IV dose (apparent clearance) was influenced by the fraction of the dose absorbed.

Apparent Volume of Distribution of ILV-094: Multiple DosePre-dose, 1, 2, 3, 4, 8, 24, 28, 96,144, 192, 240, 312, 480, 648, 816 hours post-dose on Day 14

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores at Week 2, 4, 6, 8 and 12Baseline, Week 2, 4, 6, 8, 12

PASI score is the combined assessment of lesion severity and area affected into single score range on a scale of 0 (no disease) to 72 (maximal disease), with higher scores indicating greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

Percent Change From Baseline in Target Lesion Score (TLS) at Week 2, 4, 6, 8 and 12Baseline, Week 2, 4, 6, 8, 12

TLS was based on the severity of 3 components: erythema, induration, and scaling. Severity of each component was evaluated on a 5-point scale as: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked, with higher scores reflected increased lesion severity. Scores of 3 components were summed to derive the total target lesion score, ranging from 0=none to 12=very marked, with higher scores reflected increased lesion severity.

Percent Change From Baseline in Physician Global Assessment Score at Week 2, 4, 6, 8 and 12Baseline, Week 2, 4, 6, 8, 12

Physician global assessment of disease activity was measured on an 11-point scale, ranging from 0 = no disease activity to 10 = extreme disease activity, where higher scores indicating greater disease activity.

Trial Locations

Locations (24)

Hudson Dermatology

🇺🇸

Evansville, Indiana, United States

Dawes Fretzin Clinical Research Group

🇺🇸

Indianapolis, Indiana, United States

Baylor Research Institute

🇺🇸

Dallas, Texas, United States

FARMOVS Parexel (Pty) Ltd

🇿🇦

Bloemfontein, Free State, South Africa

David Stoll, MD

🇺🇸

Beverly Hills, California, United States

Dermatology Research

🇺🇸

Santa Monica, California, United States

Mount Sinai School of Medicine

🇺🇸

New York, New York, United States

Duke Clinical Reseach Unit

🇺🇸

Durham, North Carolina, United States

Central Dermatology

🇺🇸

Saint Louis, Missouri, United States

New York University Medical Center

🇺🇸

New York, New York, United States

Dawes Fretzin Dermatology Group

🇺🇸

Indianapolis, Indiana, United States

The Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Altoona Center for Clinical Research

🇺🇸

Duncansville, Pennsylvania, United States

Innovaderm Recherches Inc

🇨🇦

Montreal, Quebec, Canada

MRA Clinical Research

🇺🇸

South Miami, Florida, United States

Queen Mary Hospital

🇭🇰

Hong Kong, Hong Kong

Stratical Medical

🇨🇦

Edmonton, Alberta, Canada

University of Alberta, Hospital Site Clinical Sciences Building

🇨🇦

Edmonton, Alberta, Canada

Parexel George

🇿🇦

George, Western Cape, South Africa

The Northern Alberta Clinical Trials and Research Centre (NACTRC)

🇨🇦

Edmonton, Alberta, Canada

Hamzavi Dermatology

🇺🇸

Fort Gratiot, Michigan, United States

K. Papp Clinical Research

🇨🇦

Waterloo, Ontario, Canada

Bio Pharma Services Inc

🇨🇦

Toronto, Ontario, Canada

Miami Research Associates

🇺🇸

South Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath